52 results
8-K
EX-99.1
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
7 May 24
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
8:01am
, MoonLake held cash, cash equivalents and short-term marketable debt securities of $547.1 million.
Research and development expenses for the quarter … and research and development programs and the anticipated timing of the results from those studies and trials, anticipated meetings with regulatory
8-K
EX-99.1
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
11 Mar 24
Regulation FD Disclosure
8:01am
the future including, without limitation, statements regarding: plans for clinical trials and research and development programs; including the initiation
8-K
EX-99.2
dthgxklv241x
11 Mar 24
Regulation FD Disclosure
8:01am
8-K
EX-99.1
utwsx94h grz9tom
29 Feb 24
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
8:03am
8-K
EX-99.1
e6877rjpe95yp3v9 b8
14 Nov 23
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
12:00am
8-K
EX-99.2
dzfz6u
6 Nov 23
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
7:55am
8-K
EX-99.1
qb1r8cm
6 Nov 23
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
7:55am
8-K
EX-99.1
0uh9ucsp712ikld1h
16 Oct 23
Regulation FD Disclosure
6:16am
8-K
EX-99.1
kqfusl
10 Aug 23
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
8:15am
424B5
wmophr53v02g75gq
29 Jun 23
Prospectus supplement for primary offering
4:02pm
424B5
vioguy5l
26 Jun 23
Prospectus supplement for primary offering
4:23pm
8-K
EX-99.1
nxvj1wsp
26 Jun 23
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
8:45am
8-K
EX-99.2
whdovw3p m9
26 Jun 23
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
8:45am